ANDOVER, Mass. - TransMedics Group, Inc. (NASDAQ:TMDX), a medical technology company specializing in organ transplant therapy, reported fourth-quarter earnings that exceeded analyst expectations ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

Vicor Corporation (NASDAQ:VICR), with a market capitalization of $2.35 billion, reported its fourth-quarter 2024 earnings, surpassing market expectations with an EPS of $0.23 against a forecast of ...

Pfizer stock has suffered as demand for the company’s top selling coronavirus products declined. The pharma giant has reached an important transition point. Right now, as an investor, you may be ...

Claims on social media suggest Pfizer's COVID vaccine has fatal side effects, referencing a US House document. However, the report includes adverse events, not side effects. Adverse events ...

James Sheppard, 25, of The Dell in Vernham Dean, was 21 years old when he used a messenger application to download 318 such pictures – some of them moving images. He also uploaded some of the images ...

A property management company responsible for several residential blocks in Andover and across the country has been suspended from its trade body for three months. FirstPort, which manages more than ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already broadest-in-class U.S. label in prostate cancer. Following an FDA approval in 2023 ...

Pfizer generated strong growth last year despite a significant drop in COVID revenue. The company's business is solid, and its growth prospects are encouraging. Investors, however, remain ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside Xtandi, reduced prostate cancer progression by 49%. The data ...